Trück, J; Jawad, S; Goldblatt, D; Roalfe, L; Snape, MD; Voysey, M; Pollard, AJ; (2016) The Antibody Response Following a Booster with Either a 10- Or 13-Valent Pneumococcal Conjugate Vaccine in Toddlers Primed with a 13-Valent Pneumococcal Conjugate Vaccine in Early Infancy. Pediatric Infectious Disease Journal , 35 (7) pp. 787-793. 10.1097/INF.0000000000001180.

Preview

Text (Accepted Manuscript) Truck et al The Antibody Response Following a Booster with Either a 10- Or 13-Valent Pneumococcal Conjugate Vaccine in Toddlers Primed with a 13-Valent Pneumococcal Conjugate Vaccine in Early Infancy AAM.pdf Download (646kB) | Preview

Abstract

BACKGROUND: Both the 13- and 10-valent pneumococcal conjugate vaccines (PCV-13; PCV-10) are immunogenic and effective against vaccine-type pneumococcal disease when given to young children. However, limited data are available regarding the interchangeability of these two vaccines. METHODS: UK children (n=178) who had previously been vaccinated with PCV-13 at 2 and 4 months were randomized to receive either a PCV-13 or a PCV-10 booster at 12 months of age. PCV-13 vaccine-type anti-polysaccharide serum IgG concentrations and opsonophagocytic assay (OPA) titers were measured before and at 1 and 12 months following vaccination. The primary objective was to assess non-inferiority of PCV-10 compared with PCV-13. RESULTS: For 8 of the PCV-10 serotypes at least 97% of participants in both groups had IgG concentrations ≥0.35 µg/ml at 1 month after vaccination; inferior responses were seen for serotypes 5 and 9V following the PCV-10 compared with the PCV-13 booster. Post-booster geometric mean IgG concentrations and OPA titers were significantly superior for most serotypes in PCV-13 compared with PCV-10 recipients whereas similar or inferior responses were seen for serotypes 4, 18C and 19F. Although some increase in antibody was seen in PCV-10 recipients against the serotypes 6A and 19A (serotypes that cross-react with 6B and 19F in PCV10, respectively) at 1-month post-booster, these responses were significantly lower than in the PCV-13 group. CONCLUSIONS: In PCV-13 primed infants, a PCV-10 booster is generally less immunogenic than a PCV-13 booster. For the 3 serotypes in PCV-10 with higher antigen content and/or conjugation to diphtheria or tetanus toxoid carrier proteins, higher or similar booster responses were seen in PCV-10 recipients. Although these findings suggest that responses are generally better with a PCV13 booster among PCV-13 primed children, the clinical significance of these differences in immunogenicity is unclear.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item